ArticleJournal of inflammation research2026
Mechanism Study of Yi-Qi-Dao-Zhi Formula in Improving Postoperative Ileus by Targeting the TLR4/NF-κB/MAPK Signaling Pathways.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Postoperative ileus (POI) commonly impedes recovery after surgical procedures. While the Yi-Qi-Dao-Zhi Formula (YQDZ) has proven its worth in treating premature ovarian insufficiency in clinical settings, the exact therapeutic mechanisms that make it tick continue to fly under the radar. Methods: This investigation employed ultra-performance liquid chromatography combined with quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF-MS/MS) to pinpoint the key bioactive compounds in YQDZ. For in vivo experiments, a POI mouse model was created through surgical intervention, and gastrointestinal transport function was assessed via charcoal ink experiments. Intestinal histopathology was examined using HE staining. The therapeutic impact of YQDZ on POI was thoroughly assessed using a battery of advanced laboratory techniques, including immunofluorescence staining, immunohistochemical analysis, Western blot procedures, real-time quantitative PCR assays, and ELISA testing. In vitro experiments involved the establishment of an M1-type inflammatory model by inducing mouse mononuclear macrophage RAW264.7 cells with LPS. Additional evaluations encompassed CCK-8 assays, flow cytometry, transcriptomic profiling, real-time PCR, and protein level examinations, all aimed at delving into the mode of action of YQDZ. Results: YQDZ steers M1 macrophage differentiation through the TLR4/NF-κB/MAPK signaling pathway. This action effectively curtails the levels of key inflammatory mediators including TNF-α, IL-1β, and IL-6. Consequently, it acts as a therapeutic agent for inflamed bowels in postoperative ileus mice, helping to restore their gastrointestinal functionality. Conclusion: The therapeutic approach of YQDZ for POI might be connected to the adjustment of the TLR4/NF-κB/MAPK signaling pathway, alongside the inhibition of macrophage polarization.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.